- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on PD-L1 in China
Total 88 results
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Wuxi People's HospitalRecruitingCancer | PD-L1 Gene MutationChina
-
Baodong QinUnknown
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsSpain, Korea, Republic of, China, Taiwan, Turkey, Greece, United States, Croatia, Serbia, Canada, Mexico, Cyprus, Georgia
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Thailand, France, Belgium, China, Germany, Greece, Argentina, Turkey, Malaysia, Portugal, Brazil, United States, Hungary, India
-
Peking University Cancer Hospital & InstituteRecruitingMelanoma | Lung Cancer | PD-L1 | PET/CTChina
-
Shanghai Cancer Hospital, ChinaUnknownLung Cancer Stage IV,EGFR-mutant,TKI,PD-L1,SBRTChina
-
Lei LiRecruitingMicrosatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Xiaohua ZhuRecruitingNSCLC Stage IV | PD-L1 Gene AmplificationChina
-
The First Hospital of Jilin UniversityRecruitingPD-L1 Positive Locally Advanced Patients With Resectable Gastric CancerChina
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaboratorsNot yet recruitingCervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant ChemoimmunotherapyChina
-
Sun Yat-sen UniversityRecruitingInduction Chemotherapy | Locally Advanced Nasopharyngeal Carcinoma | PD-L1 | EnvafolimabChina
-
Lei LiRecruitingEpithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Guohui LiRecruitingPD-1 | Immune Related Adverse EventsChina
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedHealthy Subjects | PK/PDChina
-
Shanghai International Medical CenterUnknownAdvanced Solid Tumor | PD-1 Antibody | CAR-T CellsChina
-
Ningbo Cancer HospitalUnknownAdvanced Malignancies | PD-1 Antibody | CAR-T CellsChina
-
Beijing Friendship HospitalNot yet recruiting
-
Sun Yat-sen UniversityRecruitingPD-1 Inhibitor | G-CSFChina
-
Beijing HospitalCompleted
-
Wuhan Union Hospital, ChinaRecruitingGastroesophageal Junction Cancer | PD-1 | Neoadjuvant ChemoradiotherapyChina
-
Xijing HospitalRecruitingPD-1 | Locally Advanced Gastric AdenocarcinomaChina
-
Beijing Friendship HospitalNot yet recruiting
-
Sun Yat-sen UniversityRecruitingPD-1 Inhibitor | Granulocyte Colony-Stimulating FactorChina
-
Sichuan Cancer Hospital and Research InstituteNot yet recruitingIntrahepatic Cholangiocarcinoma | Apatinib | PD-1 Antibody | Transarterial ChemoembolizationChina
-
RenJi HospitalRecruitingUpper Urinary Tract Urothelial Carcinoma | Kidney Preservation | HER-2 ADC | PD-1antibodyChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Beijing Friendship HospitalCompletedCamrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 TherapyChina
-
Shanghai Zhongshan HospitalActive, not recruitingBiliary Tract Cancer | PD-1 Antibody | Lenvatinib | GemoxChina
-
Chinese PLA General HospitalRecruitingHodgkin Lymphoma | Anti-PD-1 Antibody ResistantChina
-
Sichuan UniversityRecruitingNSCLC | PD-1 Inhibitor | Leptomeningeal Metastasis | Low Dose RadiotherapyChina
-
Fudan UniversityNot yet recruitingGastric Cancer | MSI-H | Adjuvant Therapy | PD-1 ImmunotherapyChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaboratorsRecruiting
-
Chinese PLA General HospitalRecruitingPD-1 Inhibitor Failed Patients With Classical Hodgkin LymphomaChina
-
RenJi HospitalRecruitingUrothelial Carcinoma Bladder | PD-1 InhibitorChina
-
Fudan UniversityRecruitingCarcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKIChina
-
Peking Union Medical College HospitalRecruitingHepatocellular Carcinoma | PD-1 Inhibitor | RegorafenibChina
-
Sun Yat-sen UniversityRecruitingImmunotherapy | DMMR Colorectal Cancer | Anti PD-1China
-
Sun Yat-sen UniversityRecruitingHepatocellular Carcinoma | PD-1 Inhibitor | Lenvatinib | Hepatic Arterial Infusion ChemotherapyChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
First People's Hospital of HangzhouHangzhou Cancer HospitalRecruitingStereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLCChina
-
Peking Union Medical College HospitalRecruitingAnlotinib | Anti-PD-1 Antibody | Advanced Pancreatic CancerChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFirst Affiliated Hospital of Jinan University; Shenzhen University General...RecruitingCarcinoma | Digestive System Neoplasms | Intrahepatic Cholangiocarcinoma | First-line Treatment | PD-1 InhibitorChina
-
Peking University Third HospitalCompletedPancreatic Cancer | Stereotactic Body Radiotherapy | PD-1 InhibitorsChina